Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

Headlines,BKV made a successful debut on the New York Stock Exchange, achieving a significant market capitalization.,The ...

Belite Bio Navigates Cash Challenges in Quest for Biotech Breakthrough ...

But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn ...

Edgewise Therapeutics (EWTX) stock surged after positive Phase 1 and Phase 2 trial results for its heart disease therapy ...

NEW YORK, Sept. 17 (Korea Bizwire) — Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor ...

报告还对预测期间各应用市场未来需求力度、市场规模、增长率等数据方面进行了合理评估。 报告中例举的全球氰氨化氢市场领头企业包括Alz Chem, Belite Chemical, Darong Group, Denka, Efirm Biochemistry, Kanglong Pharmaceutical, Xinmiao Chemical, Youlian Fine Chemical, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This time around, we note that Belite Bio hired Hendrik Scholl as chief medical officer. Previously, he was director of the Institute of Molecular and Clinical Ophthalmology Basel and an ...

On Thursday, H.C. Wainwright maintained a Buy rating for Belite Bio, Inc (NASDAQ:BLTE) shares, with a steady price target of $60.00. The firm's analyst highlighted the recent advancements in the ...

周四，H.C. Wainwright维持对Belite Bio, Inc (NASDAQ:BLTE)股票的买入评级，目标价格保持在60.00美元。该公司分析师强调了DRAGON II试验最近在tinlarebant药物治疗Stargardt病（STGD1）方面的进展。本周早些时候，东京医疗中心为首位患者进行了给药。这一进展是在日本成功完成 ...